DB-1418

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameDB-1418
Drug Alias NameDB-1418AVZO-1418
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > P1021 payload
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsAnti-Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursLung NeoplasmsNasopharyngeal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDuality Biologics (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDuality Biologics (Suzhou) Co LtdAvenzo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsNasopharyngeal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A